Summary of clinical efficacy and patient feedback of Abatacept (Enrisu) injection

Abatacept is a selective T cell costimulation inhibitor, mainly used to treat moderate to severe rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) and certain immune-mediated diseases. It binds to the CD28 receptor on the surface of T cells, blocking the costimulatory signal between antigen-presenting cells and T cells, thereby inhibiting T cell activation and inflammatory response. Clinical studies have shown that abatacept can effectively reduce joint pain and swelling in patients with arthritis, improve joint function and quality of life, and provide a reliable option for long-term inflammation control.

In terms of clinical efficacy in patients with rheumatoid arthritis, the results of multiple phase III clinical trials have shown that abatacept injection can significantly improve the disease activity score (DAS28) improvement rate and delay the progression of joint structural damage. After treatment with abatacept for 12 weeks to 24 weeks, most patients showed significant relief of joint swelling and pain, and inflammatory markers such asCreactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels also decreased significantly. Long-term follow-up data further showed that the drug was stable in maintaining remission and reducing the risk of relapse.

In terms of patient feedback, most users said that abatacept injection has significantly improved the ability to reduce joint pain and improve daily activities, especially when used early, it can quickly relieve symptoms and improve the quality of life. At the same time, the injection dosage form is convenient for home self-management, and some patients can take medication at home through subcutaneous injection, which reduces the frequency of hospital visits and improves treatment compliance. However, some patients report slight redness, swelling, itching or short-term low-grade fever at the injection site. Most of these side effects are mild and can be alleviated through local care or short-term symptomatic treatment.

Overall, abatacept injection has shown good clinical efficacy and safety, and is especially suitable for treating traditional non-steroidal anti-inflammatory drugs (NSAIDs) or methotrexate (MTX) patients who respond poorly. Through reasonable dosage and regular administration, patients can achieve significant improvement in joint function and quality of life. Combining patient feedback and clinical data, abatacept has become an important targeted immune intervention drug in the treatment of autoimmune joint diseases, providing an effective and long-term management treatment option for moderate to severe patients.

Reference link:https://www.drugs.com